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The prevalence of hypertension in African Americans (AAs) is higher than in other US groups; yet, few have per-
formed genome-wide association studies (GWASs) in AA. Among people of European descent, GWASs have
identified genetic variants at 13 loci that are associated with blood pressure. It is unknown if these variants
confer susceptibility in people of African ancestry. Here, we examined genome-wide and candidate gene associ-
ations with systolic blood pressure (SBP) and diastolic blood pressure (DBP) using the Candidate Gene
Association Resource (CARe) consortium consisting of 8591 AAs. Genotypes included genome-wide single-
nucleotide polymorphism (SNP) data utilizing the Affymetrix 6.0 array with imputation to 2.5 million HapMap
SNPs and candidate gene SNP data utilizing a 50K cardiovascular gene-centric array (ITMAT-Broad-CARe
[IBC] array). For Affymetrix data, the strongest signal for DBP was rs10474346 (P 5 3.6 3 1028) located near
GPR98 and ARRDC3. For SBP, the strongest signal was rs2258119 in C21orf91 (P 5 4.7 3 1028). The top IBC
association for SBP was rs2012318 (P 5 6.4 3 1026) near SLC25A42 and for DBP was rs2523586 (P 5 1.3 3
1026) near HLA-B. None of the top variants replicated in additional AA (n 5 11 882) or European-American
(n 5 69 899) cohorts. We replicated previously reported European-American blood pressure SNPs in our AA
samples (SH2B3, P 5 0.009; TBX3-TBX5, P 5 0.03; and CSK-ULK3, P 5 0.0004). These genetic loci represent
the best evidence of genetic influences on SBP and DBP in AAs to date. More broadly, this work supports that
notion that blood pressure among AAs is a trait with genetic underpinnings but also with significant complexity.
INTRODUCTION
In the USA, hypertension is more common among people of
African compared with European descent. According to data
from the National Health and Nutrition Examination Survey
(NHANES) collected between 1999 and 2004, the prevalence
of hypertension in African Americans (AAs) was 40%, com-
pared with 27% in European Americans (1,2). The risk of suf-
fering hypertensive end-organ damage including end-stage
renal disease, heart failure and stroke is also greater among
AAs than European Americans (1,3). Furthermore, in 2004,
the death rate from hypertension was three times greater in
AAs compared with European Americans (4,5).
A portion of the excess burden of hypertension among AAs
may be due to genetic susceptibility. Admixture mapping analy-
sis of hypertension suggested that African ancestry is associated
with hypertension (6). Two recent genome-wide association
studies (GWASs) of blood pressure, each involving 30 000
participants of European descent, have identified common
genetic variants at 13 loci that are associated with blood pressure
or hypertension. It is unknown at present, however, if these var-
iants confer susceptibility to hypertension in people of African
descent. Prior investigations have reported considerable differ-
ences in genetic association patterns for blood pressure and
other traits across ethnic/racial groups. These association differ-
ences may be due to differences in linkage disequilibrium (LD)
patterns, allele frequencies, causal pathways, or environmental
exposures. Therefore, the relations of genetic variants to blood
pressure must be examined within ethnicities.
The first GWAS for blood pressure phenotypes in AAs did not
identify any SNPs reaching genome-wide significance (P, 5 ×
1028) with hypertension, although six were associated with sys-
tolic blood pressure (SBP) in a secondary analysis in a subset of
508 normotensive individuals (7). The present study represents
the largest GWAS for blood pressure in AAs to date. We also
attempted replication of our top findings in individuals of
African ancestry and individuals of European ancestry. Under-
standing genetic contributions to blood pressure may provide
insight into the mechanisms underlying ethnic disparities in car-
diovascular disease, and findings may assist in more personalized
and targeted treatments to prevent target-organ damage and its
associated morbidity and mortality.
RESULTS
Study sample
The analyzed study sample included individuals from five
cohorts [Atherosclerosis Risk in Communities (ARIC) study
(n ¼ 2511); Coronary Artery Risk Development in Young
Adults (CARDIA, n ¼ 833); Cleveland Family Study (CFS,
n ¼ 489), Jackson Heart Study (JHS, n ¼ 2017) and Multi-
Ethnic Study of Atherosclerosis (MESA, n ¼ 1623); total
n ¼ 7473] for the GWAS analysis and six cohorts [ARIC
(n ¼ 2692), CARDIA (n ¼ 1134), CFS (n ¼ 530), Cardiovas-
cular Health Study (CHS; n ¼ 735), JHS (n ¼ 1916) and
MESA (n ¼ 1584); total n ¼ 8591)] for the IBC analysis.
For JHS, we excluded these individuals who were overlapped
with ARIC participants. The cohort-specific sample character-
istics are described in Table 1.
Genome-wide association of Candidate Gene Association
Resource AA cohorts for blood pressure
Meta-analysis quantile–quantile and Manhattan plots of
genome-wide SNPs including both genotyped and imputed
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for the two blood pressure phenotypes are presented in Sup-
plementary Material, Figure S1. If an SNP was genotyped,
we always reported the result based on genotyped data. In
the meta-analysis of GWAS data, one SNP for diastolic
blood pressure (DBP) and one for SBP attained genome-wide
significance (defined as P , 5 × 1028; Table 2). The strongest
signal for DBP was rs10474346 (P ¼ 3.6 × 1028) in the inter-
genic region of GPR98 and ARRDC3 on chromosome 5q14.
This SNP is in tight LD with a missense SNP (rs4377733;
pairwise r2 ¼ 0.9) in hypothetical gene LOC729040. For
SBP, the strongest signal was for rs2258119 in C21orf91 on
chromosome 21q21 (P ¼ 4.7 × 1028), which is in tight LD
with nearby rs2824495 (r2 ¼ 1.0), which is a missense SNP
in C21orf91. Suggestive evidence of association was detected
in the regions of IPO13 (rs1990151, P ¼ 7.4 × 1027), FMNL2
(rs13413144, P ¼ 5.6 × 1027) and GPD2 (rs592582, P ¼
4.5 × 1027). The regional plots of association for the genome-
wide significant loci are presented in Figure 1.
Pooled genotype data analysis was conducted for the five
cohorts with Affymetrix 6.0 genotyping data using FamCC
(8), on genotyped SNPs only. In general, the results were
highly consistent with those from the meta-analysis.
Association of SNPs on the IBC chip with blood pressure
Meta-analysis of Candidate Gene Association Resource
(CARe) cohorts with IBC chip data did not identify any
SNPs that reached the pre-specified array-wide significance
level based on the estimated effective number of independent
tests (SNPs) after adjusting for multiple testing (0.05/25 000,
P , 2.0 × 1026). There was suggestive evidence of associ-
ation with SBP for two genes NUCB2 (rs214070, P ¼
8.7 × 1026; in LD with missense SNP rs757081, r2 ¼ 0.7)
and SLC25A42 (rs2012318, P ¼ 6.4 × 1026; in LD with mis-
sense SNP rs4808907, in SFRS14, r2 ¼ 0.6); these results are
summarized in Table 3. The top results for DBP were
rs2523586 (near HLA-B, P ¼ 1.3 × 1026) and rs4930130
(near KCNQ1, P ¼ 3.2 × 1026). These and other SNPs
with P , 1024 are summarized in Supplementary Material,
Table S3.
Independent replication of top CARe SNPs in cohorts of
African and European ancestry
Replication cohorts for the study are described in detail in
Supplementary Material, Section II. Nine top SNPs (six
selected from the genome-wide meta-analysis, two selected
from the candidate gene meta-analysis and one selected
from the CARDIA GWAS) in the CARe analyses were sub-
mitted for lookup in five AA cohorts [Maywood
African-American study (n ¼ 743), Howard University
Family Study (HUFS, n ¼ 1016), the International Collabora-
tive Study on Hypertension in Blacks (ICSHIB, n ¼ 1188), the
Genetic Epidemiology Network of Arteriopathy (GENOA,
n ¼ 845) and the Women Health Initiative (WHI, n ¼ 8090)]
and in whites of European ancestry in the International Con-
sortium for Blood Pressure (ICBP; n ¼ 69 899). Criteria for
declaring replication was either 5.0 × 1028 for final
meta-analysis of GWAS SNPs or 2.0 × 1026 for final
meta-analysis of IBC SNPs. Results of replication for SBP
and DBP by replication cohort and those of the final
meta-analysis of cohorts of African ancestry are provided in
Table 4. None of the top SNPs from the Affymetrix 6.0 or
the IBC array met the a priori criteria for replication after cor-
recting for multiple comparisons. Results of replication by
cohort are displayed in Supplementary Material, Table S4.
Lookup of published SNPs from previous studies of people
with African ancestry
We examined whether published SNPs from GWAS of blood
pressure in people of African ancestry (9) could be replicated
in our sample (Supplementary Material, Table S2A). None of
the previously reported loci for SBP or DBP replicated in our
study.
Lookups of published SNPs from previous studies
including populations of European ancestry
Two large-scale GWASs in European populations have been
published, and 13 independent loci have been shown to be
associated with blood pressure at a genome-wide significant
Table 1. Study sample characteristics
Study N Male
(%)
Antihypertensive
medication (%)
Age (years) BMI (kg/m2) DBP (mmHg) SBP (mmHg)
Mean SD Mean SD Mean SD Mean SD
Affymetrix 6.0 genotyping
ARIC 2511 37.1 44.0 53.3 5.8 29.6 6.0 79.7 12.1 128.3 20.8
CARDIA 833 38.1 13.0 39.5 3.9 30.8 7.5 76.9 12.1 116.9 16.4
CFS 489 40.7 38.9 45.7 16.2 34.6 9.6 76.5 10.7 128.2 16.0
JHS 2017 38.7 46.3 49.9 11.9 32.3 7.8 80.0 10.6 124.9 18.0
MESA 1623 45.7 50.5 62.2 10.1 30.2 5.9 74.5 10.2 131.4 21.7
IBC genotyping
ARIC 2692 36.9 44.1 53.2 5.8 29.7 6.1 79.4 12.0 128.0 20.7
CARDIA 1134 40.5 13.8 39.6 3.8 30.7 7.5 77.0 12.4 117.1 16.3
CFS 530 42.1 37.7 45.2 16.1 34.2 9.6 76.4 10.8 127.7 15.8
CHS 735 37.6 51.8 73.0 5.7 28.5 5.6 75.1 11.3 141.8 22.7
JHS 1916 39.2 46.0 49.9 12.0 32.2 7.8 79.9 10.6 124.9 18.0
MESA 1584 46.1 50.9 62.2 10.1 30.2 5.9 74.6 10.3 131.7 21.6
Study characteristics are shown for cohort samples examined in meta-analysis. N, sample size—the number of individuals with genotype and phenotype data
available.
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level (10,11). We then performed one-sided test to examine if
the association evidence for these published loci can be repli-
cated in the CARe data sets. The one-sided test ensures the
effect directions are the same in both discovery and replication
samples. Of the SNPs reported in these two European GWASs
(Table 5 and Supplementary Material, Tables S2A and S2B),
we identified the following association signals in our AA
samples: rs3184504 (SH2B3, one-sided P ¼ 0.009),
rs2384550 (TBX3-TBX5, one-sided P ¼ 0.03) and rs6495122
(CSK-ULK3, one-sided P ¼ 0.0004).
DISCUSSION
This study represents the largest GWAS of blood pressure in
AAs to date including a total of 8591 individuals for discovery
and 11 882 individuals of African descent and 69 899 of Euro-
pean descent for replication. In a meta-analysis across five US
community-based cohorts using the Affymetrix 6.0 array, we
identified two novel loci, rs2258119 and rs10474346, that
reached genome-wide significance, but did not replicate in
independent African-American samples. We replicated
several previously reported European-American blood
pressure SNPs in our CARe AA samples.
Top loci for the Affymetrix 6.0 array GWAS
We identified a locus on chromosome 5 that reached genome-
wide significance for DBP in CARe African-American
cohorts. The top SNP (rs10474346, P ¼ 3.6 × 1028) is in
tight LD with a non-synonymous coding SNP rs4377733.
Genes in the region include G protein-coupled receptor 98
(GPR98) and arrestin C (ARRDC3). GRR98 is a very large
G-protein coupled receptor expressed in the central nervous
system and other tissue and implicated in Usher syndrome
characterized by hearing loss and retinitis pigmentosa. SNPs
in GPR98 have been associated with markers of hyperglyce-
mia in patients taking the antipsychotic medication olanzapine
(12). Arrestin C is a peroxisome proliferator-activated receptor
gamma (PPARG) ligand and PPARG activator. PPARs are a
family of nuclear receptors that are activated by nutrient mol-
ecules and their derivatives (13). PPARG activators may play
a role in hypertension and atherosclerosis through modifi-
cation of inflammation and the innate immunity system in vas-
cular cells (13,14).
Another locus that reached genome-wide significance for
SBP in CARe AA cohorts is on chromosome 21, where a
region was previously reported in admixture mapping analysis
(15). The top SNP at this locus, rs2258119 (P ¼ 4.7 × 1028),
is in tight LD with missense variant rs2824495 in C21orf91
(pairwise r2 ¼ 1.0). The minor allele frequencies of this
SNP in HapMap CEU and YRI samples are 21 and 34%,
respectively, which suggests that this SNP may contribute to
the association signal observed in the admixture mapping
analysis (15). This region includes CXADR (Coxsackie and
Adenovirus receptors), which encodes a tight junction
protein of the intercalated disks between cardiomyocytes.
This protein is an entry point for virus uptake in myocarditis
and is involved in cardiac remodeling (16). An SNP of inter-
est, rs1990151 on chromosome 1, showed suggestiveT
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association with SBP (P ¼ 7.4 × 1027). This is an intronic
SNP in importin beta (IPO13). Importin beta is a nuclear
transport protein that modifies nuclear availability of glucocor-
ticoids through nucleocytoplasmic shuttling (17). There is a
potential link proposed between early-onset glucocorticoid
exposure and hypertension through changes in gene expression
and function in the kidney (18). Of note, another importin beta
protein (IPO7) was identified by Adeyemo et al. (7) in a
genome-wide association analysis of a normotensive subset
of AAs.
Top SNPs from the meta-analysis of the IBC array
In our IBC array analysis, we identified suggestive evidence of
association for rs2012318, which is an intronic SNP in
SLC25A42, a carrier protein that transports cofactor coenzyme
A and adenosine 3′,5′-diphosphate into the mitochondria in
exchange for intramitochondrial (deoxy)adenine nucleotides
and adenosine 3′,5′-diphosphate (19). SNPs in this region
were associated with LDL cholesterol and triglyceride
levels in a whole genome analysis of European populations
(20).
Two tightly linked SNPs, rs4930130 and rs1791926 (r2 ¼
1.0) on chromosome 11, were associated with DBP with
P , 1 × 1025. They are in proximity to KCNQ1, which
encodes a protein for a voltage-gated potassium channel
required for the repolarization phase of the cardiac action
potential. The gene product is associated with hereditary
long QT syndrome, Romano-Ward syndrome, Jervell and
Lange-Nielsen syndrome and familial atrial fibrillation (21).
Another signal of interest was found for rs1791926, near
P2RY2 (purinergic receptor P2Y, G coupled 2) on chromo-
some 11q13.5-q14.1 that mediates vasoactive and proliferative
stimuli. There is evidence that the purinergic system may
affect the activity of epithelial sodium channel in the renal col-
lecting duct, which is responsible for re-absorption of sodium
(22,23). Genetic defects in this channel in humans have been
associated with hypertension in Liddle’s syndrome. P2Y2 (a
homolog of P2RY2) knockout mice manifest a salt resistant
hypertensive phenotype (24). A recent case–control associ-
ation study by Wang et al. (25) showed an association of
P2RY2 with hypertension in Japanese men.
Association evidence of SNPs with blood pressure in
CARDIA
It is intriguing that we observed a strong association signal in a
1.26 Mb region on chromosome 11 (smallest P ¼ 3.95 × 1029
for rs17610514; Supplementary Material, Table S1) in AAs in
the CARDIA cohort only. Although the allele frequencies for
these significant SNPs are all relatively small (,4%), the
results are unlikely due to the genotyping errors given the
number of SNPs reaching genome-wide significance. The sen-
tinel SNP is in tight LD with several missense variants in
olfactory receptor genes. The subjects recruited in CARDIA
cohort are much younger than in the other cohorts, suggesting
that the association is stronger in populations composed of
younger individuals.
A particularly important contribution of this study is the gen-
eralization of findings from two large meta-analyses of Eur-
opeans and European Americans (10,11) to individuals of
African ancestry. The three loci, near the SH2B3, TBX3-TBX5
and CSK-ULK3 genes, provide evidence for common genetic
variants influencing blood pressure phenotypes in AA and also
suggest that at least some loci may confer broad susceptibility
to hypertension across race/ethnicities.
Figure 1. Regional plots of top blood pressure loci in AAs from meta-analysis
of Affymetrix 6.0 arrays. One locus for diastolic BP (A) and two loci for SBP
(B and C). For each locus, we show the region extending to within 500 kb of
the associated SNP on either side. Statistical significance of SNPs around each
locus are plotted as 2log10(P) against chromosomal position. For each locus,
the most significant SNP is shown in blue. If the most significant SNP of a
locus is imputed SNP (as in A), then the most significant genotype SNP is
shown in blue too. Among genotyped SNPs, SNPs in yellow have r2 ≥ 0.8
with the most significant genotyped SNP. Imputed SNPs are shown in grey.
Superimposed on the plot are gene locations (green) and recombination rate
(blue). Chromosome positions are based on HapMap release 22 build 36.
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Limitations
Because multiple cohorts were used to maximize the sample
size in the analyses, heterogeneity in blood pressure measure-
ment across the centers may bias our findings toward the null.
Additionally, a substantial proportion of individuals were on
blood pressure lowering medications, which may introduce
some degree of misclassification of blood pressure. In addition,
participants in JHS and ARIC were older with a large number on
antihypertensive medications, whereas participants in CARDIA
were significantly younger than the other cohorts with only a
small percentage of participants on antihypertensive medi-
cations. We observed some evidence for heterogeneity across
studies, with SNPs in GPR98 region (for DBP) on the Affyme-
trix 6.0 array (Table 2) and SNPs in the SLC25A42 region (for
both DBP and SBP) on the IBC array (Table 3) displaying the
smallest heterogeneity P-values. Heterogeneity in the associ-
ation results across studies may have attenuated association
P-values, but also revealed mechanisms of action of genetic
variants on blood pressure.
We did not observe clear replication of our two top loci that
were genome-wide significant in our CARe GWAS. Our repli-
cation cohorts were generally small thus reducing the power to
replicate significant findings. We estimated the proportion of
variation in blood pressure associated with the two genome-
wide significant SNPs at 0.4% in CARe samples. Because
of the winner’s curse and the variation in LD between a true
causal SNP and our identified SNP, our effect size may be
overestimated, which may contribute to failure to replicate.
In addition, population admixture may result in different LD
patterns for the African-American samples from different geo-
graphical regions because the LD is dependent on the admix-
ture proportion. It has been reported that the admixture
proportion rate is different across the African-American popu-
lation (26,27). Thus, replication analysis can be challenging in
African-American populations.
These limitations are leveraged against the advantage of
using large community-based cohorts of AAs for this analysis
and the implementation of quality-control procedures in indi-
vidual examination centers and the harmonization of imputa-
tion strategies and analytical methods.
CONCLUSIONS
We found evidence of genetic influences on SBP and DBP.
Evidence of association in our GWAS was found for DBP
(rs10474346 on chromosome 5 near GPR98 and ARRDC3)
and for SBP (rs2258119 on chromosome 21in C21orf91).
Caution should be paid because the two top SNPs identified
in CARe GWAS were not replicated in independent cohorts
of African ancestry, and further replication efforts with large
sample size are warranted.
Of note, several previously reported EA blood pressure
SNPs did replicate in our CARe AA samples. These SNPs
are in the regions of SH2B3, TBX3-TBX5 and CSK-ULK3.
Implications
We identified genetic variants that reached genome-wide sig-
nificance for SBP and DBP in a large number of AAs from theT
a
b
le
3
.
T
o
p
as
so
ci
at
ed
S
N
P
s
fo
r
b
lo
o
d
p
re
ss
u
re
in
A
A
s
fr
o
m
m
et
a-
an
al
y
si
s
o
f
IB
C
ar
ra
y
s
B
P
tr
ai
t
S
N
P
ID
C
h
r
P
o
si
ti
o
n
T
y
p
e
N
ea
re
st
g
en
e
E
ff
ec
t
al
le
le
E
ff
ec
t
al
le
le
fr
eq
u
en
cy
O
th
er
al
le
le
C
A
R
e
m
et
a-
an
al
y
si
s,
D
B
P
C
A
R
e
m
et
a-
an
al
y
si
s,
S
B
P
B
et
a
S
E
P
-v
al
u
e
H
et
er
o
g
en
ei
ty
P
B
et
a
S
E
P
-v
al
u
e
H
et
er
o
g
en
ei
ty
P
A
A
s S
B
P
rs
1
2
4
0
8
3
3
9
1
1
5
4
6
2
2
1
3
4
Im
p
u
te
d
R
H
B
G
A
0
.0
8
G
2
1
.5
0
0
.4
4
6
.5
5
×
1
0
2
4
0
.2
7
2
3
.3
2
0
.7
5
8
.6
4
×
1
0
2
6
0
.5
3
S
B
P
rs
2
1
4
0
7
0
1
1
1
7
2
6
1
8
9
3
G
en
o
ty
p
ed
N
U
C
B
2
A
0
.0
6
T
0
.8
3
0
.3
9
3
.4
2
×
1
0
2
2
0
.1
6
2
.9
7
0
.6
7
8
.6
5
×
1
0
2
6
0
.2
4
S
B
P
rs
6
5
1
1
0
1
8
1
9
1
9
0
4
7
7
0
5
Im
p
u
te
d
S
L
C
2
5
A
4
2
G
0
.3
5
A
0
.5
9
0
.1
9
1
.6
9
×
1
0
2
3
0
.0
8
1
.4
3
0
.3
2
5
.8
3
×
1
0
2
6
0
.0
3
S
B
P
rs
1
2
9
8
5
7
9
9
1
9
1
9
0
4
8
5
7
5
Im
p
u
te
d
S
L
C
2
5
A
4
2
C
0
.3
3
T
0
.6
1
0
.1
9
1
.2
9
×
1
0
2
3
0
.1
5
1
.4
8
0
.3
2
3
.2
4
×
1
0
2
6
0
.0
9
S
B
P
rs
2
0
1
2
3
1
8
1
9
1
9
0
6
9
2
4
0
G
en
o
ty
p
ed
S
L
C
2
5
A
4
2
C
0
.3
5
T
0
.5
8
0
.1
9
1
.9
0
×
1
0
2
3
0
.0
9
1
.4
2
0
.3
1
6
.4
2
×
1
0
2
6
0
.0
3
S
B
P
rs
1
1
6
6
6
6
2
7
1
9
1
9
0
7
2
2
3
8
Im
p
u
te
d
S
L
C
2
5
A
4
2
C
0
.3
5
T
0
.5
9
0
.1
9
1
.5
5
×
1
0
2
3
0
.0
9
1
.4
7
0
.3
2
3
.0
0
×
1
0
2
6
0
.0
3
S
B
P
rs
1
0
4
1
7
9
7
4
1
9
1
9
0
8
3
0
7
0
Im
p
u
te
d
S
L
C
2
5
A
4
2
C
0
.3
5
T
0
.5
9
0
.1
9
1
.5
7
×
1
0
2
3
0
.0
6
1
.4
6
0
.3
2
3
.7
1
×
1
0
2
6
0
.0
3
B
et
a,
th
e
ef
fe
ct
si
ze
o
n
b
lo
o
d
p
re
ss
u
re
in
m
m
H
g
,
p
er
al
le
le
b
as
ed
o
n
th
e
ad
d
it
iv
e
g
en
et
ic
m
o
d
el
.
2278 Human Molecular Genetics, 2011, Vol. 20, No. 11
CARe consortium that did not replicate in a meta-analysis of
cohorts of African ancestry. To our knowledge, these genetic
loci represent the best evidence of genetic influences on SBP
and DBP in AAs to date. Hypertension represents the
leading cause of death from cardiovascular disease in AAs.
Our study lends support to prior admixture analyses, which
indicate that blood pressure represents a complex disease
trait with genetic underpinnings within the AA community.
Further investigation of the genetic loci identified in our analy-
sis including replication efforts is warranted. Identification of
potential genetic loci implicated in hypertension represents a
unique opportunity to introduce new treatment and manage-
ment strategies for this high-risk population.
MATERIALS AND METHODS
Study sample
NHLBI’s CARe Study includes six cohort studies with AA
representation: the ARIC Study, the CHS, the CARDIA, the
CFS, the JHS and MESA (see Supplementary Material,
Section I, for sampling details). Each study adopted collabor-
ation guidelines and established a consensus on phenotype
harmonization, covariate selection and an analytical plan for
within-study genetic association and prospective
meta-analysis of results across studies. Each study received
institutional review board approval of its consent procedures,
examination and surveillance components, data security
measures and DNA collection and its use for genetic research.
All participants in each study gave written informed consent
for participation in the study, and the conduct of genetic
research. AA samples from five cohorts (ARIC, CARDIA,
CFS, JHS and MESA) had genome-wide genotyping using
the Affymetrix Genome-Wide Human SNP Array 6.0 array
and blood pressure data for association analysis. Six cohorts
(ARIC, CARDIA, CFS, CHS, JHS and MESA) had candidate
gene genotyping in AAs using the Illumina iSelect
HumanCVD bead array (28). We excluded individuals
younger than 18 years of age.
Genotyping and quality control
Quality control of genotyping data was performed using
PLINK (29). Quality-control efforts were conducted at two
levels: exclusion of individuals and exclusion of SNPs.
Samples with a genotyping success rate of ,95% were
removed. An inbreeding coefficient was calculated and used
as a measure of heterozygosity. Outliers for heterozygosity
(defined as less than 24 SD or .4 SD beyond the mean)
were removed because of possible DNA contamination or
poor DNA quality. For population-based cohorts, pair-wise
identity-by-descent score was calculated and for each pair of
identical samples, the sample with the lowest genotyping
success rate was removed. In addition, samples that shared
5% or more of their genome with other samples also were
excluded. Multidimensional scaling (MDS) was used to esti-
mate population substructure and the identified outliers were
removed.
There were 1176 SNPs that mapped to more than one locus
in the human genome that were excluded from analysis. Indi-
vidual SNPs were also excluded if they had a call rate of less
than 90% or were monomorphic. For family data, Mendelian
inconsistency was checked using PLINK and the correspond-
ing SNPs were removed. No SNPs were removed due to sig-
nificant deviation from Hardy–Weinberg equilibrium (HWE)
because the African-American population is an admixed popu-
lation, which may result in departure from HWE.
Genotype imputation
SNP imputation was performed using MACH and the HapMap
phase 2 data sets (build 36 release 22) employing a similar
strategy as that used by Kang et al. (9). In order to address
the admixture component of our African-American popu-
lation, a reference panel consisting of equal proportions of
the YRI and CEU HapMap-phased haplotypes (using only
SNPs found in both YRI and CEU panels, i.e. 2.2 million
SNPs) was constructed. Because the CARe project had both
IBC array and Affymetrix 6.0 data genotypes on the 8500
individuals of African ancestry, it was possible to assess the
Table 4. Meta-analysis of CARe and additional African-origin cohorts, as well as the P-values in ICBP
SNP ID Chr Position Type Nearest gene SBP DBP
Meta P ICBP P Meta P ICBP P
rs10474346 5 90 599 895 Affy6 Imputed GPR98/ARRDC3 9.96 × 1023 5.19 × 1021 1.02 × 1023 5.65 × 1021
rs13413144 2 153 183 499 Affy6 Imputed FMNL2 9.28 × 1024 4.22 × 1021 1.06 × 1021 8.00 × 1021
rs17610514a 11 55 652 374 CARDIA Olfactory 8.50 × 1025 2.59 × 1021 3.90 × 1025 2.20 × 1021
rs1990151 1 44 186 879 Affy6 Genotyped IPO13 1.14 × 1023 8.20 × 1021 8.63 × 1023 8.14 × 1021
rs2012318 19 19 069 240 IBC Genotyped SLC25A42 5.68 × 1026 5.92 × 1021 6.21 × 1023 6.04 × 1021
rs214070b 11 17 261 893 IBC Genotyped NUCB2 NA 3.23 × 1022 NA 1.67 × 1022
rs2258119 21 18 089 350 Affy6 Genotyped C21orf91 5.00 × 1024 5.28 × 1021 1.41 × 1022 6.54 × 1021
rs592582 2 157 481 632 Affy6 Imputed GPD2 9.15 × 1023 9.16 × 1021 1.22 × 1021 6.59 × 1021
rs7709572 5 90 592 789 Affy6 Genotyped GPR98 1.38 × 1022 4.56 × 1021 6.49 × 1024 5.68 × 1021
Meta P, P-value by combining all cohorts of African ancestry;
ICBP P, one-sided P-value in ICBP data. For SNPs genotyped in Affy6, P-value, 5 × 1028 is considered as statistically significant. For SNPs genotyped in IBC
chip, P-value ,2 × 1026 is considered as statistically significant.
aSNP rs17610514, failed WHI QC due to low concordance rate among duplicates (,98%) and/or low call rate (,95%) and thus was not included in the
meta-analysis.
bSNP rs214070 was not genotyped in the cohorts of African ancestry except CARe.
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Table 5. Lookup of top SNPs for SBP and DBP from the meta-analysis of CHARGE and Global BPgen
SNP identifier Chr Position Nearest gene Alleles
(coded/other)
CHARGE + Global BPgen
meta-analysis
CARe meta-analysis, DBP CARe meta-analysis, SBP
Beta SE P-value Effect
allele
Other
allele
Effect P-value Effect
allele
Other
allele
Effect P-value
SBP
rs12046278a 1 10 722 164 CASZ T/C 20.53 0.12 4.77 × 1026 C T 0.40 0.23 C T 0.06 0.92
rs7571613a 2 190 513 907 PMS1 A/G 20.54 0.13 1.90 × 1025 G A 20.16 0.46 G A 20.28 0.45
rs448378 3 170 583 593 MDS1 A/G 20.51 0.10 1.18 × 1027 A G 0.15 0.42 A G 0.13 0.68
rs2736376a 8 11 155 175 MTMR9 C/G 20.48 0.15 9.15 × 1024 C G 20.31 0.13 C G 20.47 0.18
rs1910252a 8 49 569 915 EFCAB1 T/C 20.43 0.13 6.13 × 1024 T C 0.03 0.90 T C 20.23 0.51
rs11014166a 10 18 748 804 CACNB A/T 0.50 0.10 7.03 × 1027 T A 20.20 0.44 T A 20.30 0.50
rs1004467a 10 104 584 497 CYP17A A/G 1.05 0.16 1.28 3 10210 G A 0.01 0.97 G A 20.31 0.48
rs381815 a 11 16 858 844 PLEKHA T/C 0.65 0.11 1.89 3 1029 T C 0.41 0.07 T C 0.62 0.10
rs2681492a 12 88 537 220 ATP2B1 T/C 0.85 0.13 3.76 3 10211 C T 20.18 0.54 C T 20.22 0.65
rs3184504a 12 110 368 991 SH2B3 T/C 0.58 0.10 4.52 3 1029 T C 0.53 0.14 T C 1.61 9.13 × 1023
DBP
rs13423988a 2 68 764 770 GPR73-ARHGAP25 T/C 0.33 0.08 5.00 × 1025 T C 20.10 0.62 T C 0.08 0.81
rs13401889a 2 190 618 804 MST T/C 20.31 0.08 4.82 × 1025 T C 20.01 0.94 T C 0.16 0.63
rs9815354a 3 41 887 655 ULK4 A/G 0.49 0.08 2.54 3 1029 A G 0.16 0.49 A G 0.26 0.40
rs7016759 8 49 574 969 EFCAB1 T/C 0.30 0.08 2.29 × 1024 C T 20.27 0.50 C T 20.64 0.44
rs11014166a 10 18 748 804 CACNB2 A/T 0.37 0.06 1.24 3 1028 T A 20.20 0.44 T A 20.30 0.50
rs11024074 11 16 873 795 PLEKHA7 T/C 20.33 0.07 1.20 × 1026 C T 0.45 0.20 C T 0.52 0.13
rs2681472a 12 88 533 090 ATP2B A/G 0.50 0.08 1.47 3 1029 G A 20.40 0.20 G A 20.61 0.25
rs3184504a 12 110 368 991 SH2B3 T/C 0.48 0.06 2.58 3 10214 T C 0.53 0.14 T C 1.61 9.13 × 1023
rs2384550 12 113 837 114 TBX3-TBX5 A/G 20.35 0.06 3.75 3 1028 A G 20.35 0.07 A G 20.75 0.03
rs6495122a 15 72 912 698 CSK-ULK3 A/C 0.40 0.06 1.84 3 10210 C A 20.51 0.02 C A 21.32 3.74 × 1024
SNPs in boldface attained P , 5 × 1028 in meta-analysis of CHARGE and Global BPgen.
aResults of SNPs are from imputed SNPs.
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quality of the imputation process. The observed concordance
was 95.6%, which is comparable to previous studies (30).
Imputation was performed for the Affymetrix 6.0 data only.
Phenotype modeling
SBP and DBP were modeled at the first examination for ARIC,
CHS, MESA and JHS, and at the most recent examination for
CARDIA and CFS in order to minimize the effect of extreme
age differences between the cohorts. For ARIC and JHS,
seated blood pressure was measured with a random-zero
sphygmomanometer three times with the last two measure-
ments averaged. For CARDIA, seated BP was measured on
the right arm following 5 min rest using a random-zero sphyg-
momanometer. SBP and DBP were recorded as Phase I and
Phase V Korotkoff sounds. Three measurements were taken
at 1 min intervals with the average of the second and third
measurements taken as the blood pressure value. For CFS,
blood pressure was measured using a mercury sphygmoman-
ometer and was the average of nine readings (three each
made over three intervals in an 18 h period). Three measures
were made supine before bed, three measures were made
awake supine after bed and three were measured awake
while sitting. For MESA, resting seated blood pressure was
measured three times at 1 min intervals using an automated
oscillometric sphygmomanometer (Dinamap PRO 100, Criti-
kon); the average of the second and third blood pressure
measurements was used for these analyses. For individuals
taking antihypertensive medication, we added 10 and
5 mmHg to the measured SBP and DBP (31), respectively,
to account for treatment effect. Continuous DBP and SBP
were adjusted for age, age2, sex and body mass index (BMI)
in linear regressions. Residuals were calculated and
applied within cohort for analysis of genotype–phenotype
associations.
Statistical analyses
Within each cohort, the first 10 main eigenvectors from prin-
cipal components (PCs) were calculated and included in the
model testing genotype–phenotype association. The PCs
were calculated based on selected ancestry informative
markers. For comparison, we also calculated the PCs using
the method described in Zhu et al. (8), in which the eigenvec-
tors were calculated based on only unrelated individuals. PCs
were then calculated for all individuals, including family
members. Additionally in this method, all SNPs were used
to calculate PCs. The results between the two methods were
consistent, except for a few individuals (Supplementary
Material, Figure S2). We did not find that the discrepancy
affected final association results. For all data sets except
CFS, which includes family data sets, association of SNPs
with SBP and DBP was tested by linear regression with addi-
tive genetic model using PLINK; for CFS, association was
tested using a linear mixed-effect model that accounted for
family structure (32).
Meta-analysis of results was carried out using the inverse-
variance weighting method in METAL (http://www.sph.um
ich.edu/csg/abecasis/metal/). Genomic control was carried
out on cohort-specific test statistics and used to adjust results
within each study.
For comparison, analysis of pooled raw data from the five
cohorts genotyped with the Affymetrix 6.0 array was carried
out with FamCC (8). Cohort-specific genotypes and standar-
dized DBP or SBP residuals were pooled together. PCs were
calculated for all unrelated individuals and predicted for
related individuals. Genotype–phenotype association was
tested using a linear regression model with adjustment for
the first 10 PCs.
Previously published genome-wide significant SNP associ-
ations with blood pressure 7, 9 and 10 were examined. If the
published SNPs were not available in either genotyped SNPs
or imputed SNPs in the current study, we used SNPs in a
strong LD with the sentinel SNPs as proxies.
Loci with a P-value of ,1 × 1026 for the GWAS data and
of ,1 × 1025 for IBC data were selected for replication
analysis in independent cohorts of African and European
ancestry. SNPs in LD (r2 ≥ 0.5) were considered to represent
the same signal; consequently, the SNP with the smallest
P-value at a locus was selected for replication analysis.
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